Case 1

Case 2

Case 3

Case 4

Age at discovery

24

65*

37

73

Mode of revelation

Ketoacidosis

Ketoacidosis

Without ketosis

Ketoacidosis

HbA1c (%)

5.9

9.3

5.4

8.8

Anti-langherans beta cell antibodies

Negative

Negative

Negative

Positive:

anti GAD anti ZnT8 anti IA2

C Peptide

Undetectable

Undetectable

Undetectable

Undetectable

BMI (kg/m²)

18.9

24.5

20.3

31.1

Immune checkpoint inhibitor used at the diagnostic

Nivolumab

and Ipilimumab

Nivolumab

and Ipilimumab

Nivolumab

Nivolumab

Duration of treatment (week)

4

4

33

6

number of cure

2

2

17

3